https://ir.opusgtx.com/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/_3f85a7dcbfea56422a5e0fee0b561249/ocuphire/files/theme/images/logo-sm.png Equisolve Investor Relations Suite https://ir.opusgtx.com/press-releases/detail/532/opus-genetics-to-present-at-the-2026-jefferies-global-healthcare-conference Wed, 27 May 26 08:00:00 -0400 https://ir.opusgtx.com/press-releases/detail/532/opus-genetics-to-present-at-the-2026-jefferies-global-healthcare-conference https://ir.opusgtx.com/press-releases/detail/531/opus-genetics-to-present-at-the-rbc-capital-markets-2026-global-healthcare-conference Wed, 13 May 26 07:00:00 -0400 https://ir.opusgtx.com/press-releases/detail/531/opus-genetics-to-present-at-the-rbc-capital-markets-2026-global-healthcare-conference https://ir.opusgtx.com/press-releases/detail/530/opus-genetics-announces-financial-results-for-first-quarter-2026-and-provides-corporate-update Tue, 12 May 26 07:00:00 -0400 https://ir.opusgtx.com/press-releases/detail/530/opus-genetics-announces-financial-results-for-first-quarter-2026-and-provides-corporate-update https://ir.opusgtx.com/press-releases/detail/529/opus-genetics-presents-clinical-and-preclinical-data-at-arvo-2026-demonstrating-continued-pipeline-advancement-in-inherited-retinal-diseases Thu, 07 May 26 16:30:00 -0400 https://ir.opusgtx.com/press-releases/detail/529/opus-genetics-presents-clinical-and-preclinical-data-at-arvo-2026-demonstrating-continued-pipeline-advancement-in-inherited-retinal-diseases https://ir.opusgtx.com/press-releases/detail/528/opus-genetics-completes-enrollment-in-cohort-1-of-phase-12-opgx-best1-gene-therapy-study Thu, 07 May 26 07:00:00 -0400 https://ir.opusgtx.com/press-releases/detail/528/opus-genetics-completes-enrollment-in-cohort-1-of-phase-12-opgx-best1-gene-therapy-study https://ir.opusgtx.com/press-releases/detail/527/opus-genetics-announces-fda-acceptance-of-opgx-lca5-into-rare-disease-evidence-principles-rdep-program Mon, 04 May 26 16:30:00 -0400 https://ir.opusgtx.com/press-releases/detail/527/opus-genetics-announces-fda-acceptance-of-opgx-lca5-into-rare-disease-evidence-principles-rdep-program https://ir.opusgtx.com/press-releases/detail/526/opus-genetics-to-participate-in-leading-medical-conferences-in-may-2026 Mon, 27 Apr 26 08:00:00 -0400 https://ir.opusgtx.com/press-releases/detail/526/opus-genetics-to-participate-in-leading-medical-conferences-in-may-2026 https://ir.opusgtx.com/press-releases/detail/525/opus-genetics-announces-data-presentations-at-the-2026-american-society-of-cataract-and-refractive-surgery-annual-meeting Fri, 10 Apr 26 06:59:00 -0400 https://ir.opusgtx.com/press-releases/detail/525/opus-genetics-announces-data-presentations-at-the-2026-american-society-of-cataract-and-refractive-surgery-annual-meeting https://ir.opusgtx.com/press-releases/detail/524/opus-genetics-solidifies-leadership-position-in-gene-therapy-development-for-inherited-retinal-diseases-with-strategic-long-term-financing-by-oberland-capital Mon, 06 Apr 26 07:00:00 -0400 https://ir.opusgtx.com/press-releases/detail/524/opus-genetics-solidifies-leadership-position-in-gene-therapy-development-for-inherited-retinal-diseases-with-strategic-long-term-financing-by-oberland-capital https://ir.opusgtx.com/press-releases/detail/523/opus-genetics-named-to-fast-companys-annual-list-of-the-worlds-most-innovative-companies-of-2026 Tue, 24 Mar 26 07:00:00 -0400 https://ir.opusgtx.com/press-releases/detail/523/opus-genetics-named-to-fast-companys-annual-list-of-the-worlds-most-innovative-companies-of-2026